Prostate cancer Tx: Therapeutic options based on tumor grade, life expectancy, and patient preferences

Geriatrics

Volumn 56, Issue 2, 2001, Pages 39-52

  Cohen, S P ^a   Jaskulsky, S R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; DOCETAXEL; PACLITAXEL; PAMIDRONIC ACID; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CRYOSURGERY; HUMAN; LIFE EXPECTANCY; MALE; MULTIMODALITY CANCER THERAPY; PATIENT ATTITUDE; PHYSICAL EXAMINATION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK FACTOR; TREATMENT PLANNING;

AGE FACTORS; BIOPSY; DECISION MAKING; HUMANS; LIFE EXPECTANCY; LIFE STYLE; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 0035128251     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Prostate cancer: When to offer screening in the primary care setting
2. Cancer statistics, 2000
3. Vasectomy and risk of prostate cancer
4. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial
5. How to use prostate-specific antigen in the early detection or screening for prostatic carcinoma
6. Prostate cancer detection in a clinical urology practice by ultrasonography, digital rectal examination and prostate specific antigen
7. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
8. Serum PSA levels after 52 weeks of therapy with finasteride, terazosin, combination and placebo: Results of the VA Cooperative Study #359
9. Screening for prostate cancer. Why the controversy?
10. Prostate-specific antigen: Current status
11. Interpretation of the prostate-specific antigen clinical research studies for the detection of prostate cancer
12. Complication rates and risk factors of ultrasound-guided transrectal core biopsies of the prostate in a population-based screening program
13. Biological determinants of cancer progression in men with prostate cancer
14. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update
15. The use of prostate specific antigen in staging patients with newly diagnosed prostate cancer
16. Cancer control and quality of life following anatomical radical retropubic prostatectomy. Results after 10 years
17. High-precision conformal radiotherapy (HPCRT) of prostate cancer: A new technique for exact positioning of the prostate at the time of treatment
18. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer
19. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
20. Modern prostate brachytherapy. Prostate-specific antigen results in 219 patients with up to 12 years of observed follow-up
21. Cryosurgical ablation of the prostate: Two-year prostate-specific antigen and biopsy results
22. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate
23. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement. A prospective randomized study
24. Combined androgen blockade for the treatment of patients with metastatic prostate cancer: Summary of 15 years of clinical research
25. Intermittent androgen deprivation for clinically localized prostate cancer. Initial experience
26. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy
27. Bisphosphonates in prostatic carcinoma
28. Hormone and antihormone withdrawal: Implications for the management of androgen-independent prostate cancer
29. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
30. Paclitaxel in the treatment of hormone-refractory prostate cancer